COMPANY PROFILE

Rezubio Pharmaceuticals

Explore full profile

Reinventing how medicines reach diseased tissues

Zhuhai, ChinaFounded 2019Biotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Rezubio Pharmaceuticals

Rezubio Biotech is a pioneering company in the field of medicinal chemistry and disease biology, focusing on developing advanced tissue-targeting platforms to combat various diseases. The company serves pharmaceutical and biotechnology clients, operating primarily in the biotech and healthcare markets. Rezubio's business model revolves around research and development, leveraging its proprietary technology to create innovative drug solutions. Revenue is generated through partnerships, licensing agreements, and direct sales of their developed therapies. The leadership team boasts extensive experience in scientific innovation and successful entrepreneurial ventures, ensuring a robust pipeline of cutting-edge treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Zhuhai, China
Open positions: None listed
Dealroom signal: 21.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Pharmaceutical, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2025	$14M	$55M	Frees Fund · River Head Capital	↗
SEED✓Equity / VC	Feb 2023	$1.4M	$5.5M	River Head Capital	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Rezubio Pharmaceuticals website traffic

Latest recorded traffic for Rezubio Pharmaceuticals is 930 monthly website visits, up 27.4% over the last three months.

Latest monthly visits930 3-month web change+27.4%

Monthly website visitsFeb 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BBBeijing Van Enkel BiotechnologyDeveloping novel anti-cancer drugs targeting signaling pathways	China	Operational	—	$30M	$110M
CGCSPC Pharmaceutical GroupCSPC Pharmaceutical Group is a pharmaceutical group in China	Shijiazhuang, China	Operational
PBPunozhi Pharmaceutical BiotechnologyAI-powered drug discovery for hard-to-drug targets	China	Operational
TATres AlchemixAI-powered drug discovery platform using quantum chemical calculations	Fukuoka, Japan	Operational
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
LBLaguna BioDevelops immunotherapies that activate the innate immune system to combat solid tumors	Berkeley, United States	Operational